checkAd
    Startseite > Aktien > Aura Biosciences > Nachrichten
    Aura Biosciences Aktie
    7,3100
     
    USD
    -3,05 %
    -0,2300 USD
    Letzter Kurs 11.05.24 Nasdaq
    7,3100
     
    USD
    600 STK
    Geldkurs 10.05.24
    7,3300
     
    USD
    300 STK
    Briefkurs 10.05.24
    ISIN: US05153U1079 · WKN: A3C6D1 · SYM: AURA · USA

    Neueste Nachrichten

    Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
    09.05.24 · globenewswire · Aura Biosciences
    Aura Biosciences to Participate in Upcoming Investor Conferences
    08.05.24 · globenewswire · Aura Biosciences
    Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    27.03.24 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences to Participate in Upcoming Investor Conferences
    26.02.24 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
    07.12.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
    09.11.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences to Participate in Upcoming Investor Conferences
    08.11.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences Announces Pricing of Public Offering of Common Stock
    07.11.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences Announces Proposed Public Offering of Common Stock
    06.11.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
    06.11.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
    31.10.23 · Business Wire (engl.) · Aura Biosciences
    Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
    02.10.23 · Business Wire (engl.) · Aura Biosciences